<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of their reservoir hosts. When transmitted to humans, they cause" exact="hemorrhagic fever with renal syndrome" post="(HFRS) in Asia and Europe and hantavirus (cardio) pulmonary"/>
 <result pre="When transmitted to humans, they cause hemorrhagic fever with renal" exact="syndrome" post="(HFRS) in Asia and Europe and hantavirus (cardio) pulmonary"/>
 <result pre="renal syndrome (HFRS) in Asia and Europe and hantavirus (cardio)" exact="pulmonary" post="syndrome (HPS) in the Americas. Clinical studies have shown"/>
 <result pre="syndrome (HFRS) in Asia and Europe and hantavirus (cardio) pulmonary" exact="syndrome" post="(HPS) in the Americas. Clinical studies have shown that"/>
 <result pre="series of variously substituted 5,6-dichloro-1(2)-phenyl-1(2)H-benzo[d][1,2,3]triazole derivatives active against the human" exact="respiratory" post="syncytial virus (HRSV). Interestingly, several 2-phenyl-benzotriazoles resulted in fairly"/>
 <result pre="are classified as emerging viruses that cause two life-threatening diseases:" exact="hemorrhagic fever with renal syndrome" post="(HFRS) and orthohantaviruses pulmonary syndrome (HPS), also known as"/>
 <result pre="viruses that cause two life-threatening diseases: hemorrhagic fever with renal" exact="syndrome" post="(HFRS) and orthohantaviruses pulmonary syndrome (HPS), also known as"/>
 <result pre="life-threatening diseases: hemorrhagic fever with renal syndrome (HFRS) and orthohantaviruses" exact="pulmonary" post="syndrome (HPS), also known as hantavirus cardiopulmonary syndrome (HCPS)"/>
 <result pre="diseases: hemorrhagic fever with renal syndrome (HFRS) and orthohantaviruses pulmonary" exact="syndrome" post="(HPS), also known as hantavirus cardiopulmonary syndrome (HCPS) [1]."/>
 <result pre="and orthohantaviruses pulmonary syndrome (HPS), also known as hantavirus cardiopulmonary" exact="syndrome" post="(HCPS) [1]. Small mammals are natural hosts of orthohantavirus,"/>
 <result pre="humans through the aerosol route. They are responsible for persistent" exact="infections" post="without evident illness signs in their hosts [3]. The"/>
 <result pre="respectively. The two surface glycoproteins, before being exposed on the" exact="viral" post="surface, are post-translationally processed via the endoplasmic reticulum and"/>
 <result pre="virion with N protein and, most probably, with RdRp. The" exact="viral" post="RdRp mediates the genomic and anti-genomic viral RNAs and"/>
 <result pre="with RdRp. The viral RdRp mediates the genomic and anti-genomic" exact="viral" post="RNAs and the transcription of viral mRNAs exclusively in"/>
 <result pre="the genomic and anti-genomic viral RNAs and the transcription of" exact="viral" post="mRNAs exclusively in the cytoplasm [6]. Over the last"/>
 <result pre="few years, the search for an effective treatment for orthohantaviruses" exact="infections" post="has undergone a considerable increase [7]. Ribavirin (RBV), a"/>
 <result pre="in patients with HPS. Furthermore, the use of RBV is" exact="limited" post="by its myelosuppression and toxicity [12]. Besides RBV, the"/>
 <result pre="HPS. Furthermore, the use of RBV is limited by its" exact="myelosuppression" post="and toxicity [12]. Besides RBV, the use of some"/>
 <result pre="agents is strongly desirable. At the present time, a very" exact="limited" post="number of antivirals have been tested for orthohantavirus [14]."/>
 <result pre="series of 5,6-dichloro1(2)phenyl-benzotriazole derivatives that are active against te human" exact="respiratory" post="syncytial virus (HRSV) in low micromolar range with low"/>
 <result pre="to further investigate if these derivatives are able to inhibit" exact="viral infection" post="processes of other negative sense RNA virus families, we"/>
 <result pre="further investigate if these derivatives are able to inhibit viral" exact="infection" post="processes of other negative sense RNA virus families, we"/>
 <result pre="and 1-(4-(5,6-dimethyl-2H-benzotriazol-2-yl)phenyl)-3-alkylureas (4k-n) were obtain as recently described [20,21]. 2.2." exact="General" post="Procedure for Preparation of Derivatives 3f, j and 4f,"/>
 <result pre="ethanol. 2.2.1. N-(4-(2H-benzo[d][1,2,3]triazol-2-yl)phenyl)-4-methylbenzamide (3f) Compound was obtained in 80% of" exact="total" post="yield; m.p. 266–268 °C; TLC (petroleum spirit/ethyl acetate 1/1),"/>
 <result pre="H). 2.2.2. N-(4-(2H-benzo[d][1,2,3]triazol-2-yl)phenyl)-3,4,5-trimethoxybenzamide (3j) Compound was obtained in 30% of" exact="total" post="yield; m.p. 227–229 °C; TLC (petroleum spirit/ethyl acetate 7/3),"/>
 <result pre="2.2.3. N-(4-(5,6-dimethyl-2H-benzo[d][1,2,3]triazol-2-yl)phenyl)-4-methylbenzamide (4f) This compound was obtained in 46% of" exact="total" post="yield; m.p. 295–296 °C; TLC (petroleum spirit/ethyl acetate 7/3),"/>
 <result pre="2.2.4. N-(4-(5,6-dimethyl-2H-benzo[d][1,2,3]triazol-2-yl)phenyl)-3,4,5-trimethoxybenzamide (4j) This compound was obtained in 20% of" exact="total" post="yield; m.p. 272–273 °C; TLC (petroleum spirit/ethyl acetate 6/4),"/>
 <result pre="experiments. Vero E6 cells (ATCC CRL 1586) were maintained in" exact="complete" post="EMEM (minimum essential medium with Earle’s salt, 25mM Hepes"/>
 <result pre="was purchased from Sigma–Aldrich Co. (St. Louis, MO, USA). The" exact="primary" post="antibody, rabbit anti-Malacky Ab, was obtained from Dr. Boris"/>
 <result pre="anti-Malacky Ab, was obtained from Dr. Boris Klempa, Berlin. The" exact="secondary" post="antibody was goat anti-rabbit IgG (H+L) HRP conjugate (Cat."/>
 <result pre="were then washed five times with washing buffer and a" exact="secondary" post="goat anti-rabbit IgG antibody conjugated to horseradish peroxidase (HRP)"/>
 <result pre="min) to remove debris and measured for the presence of" exact="infectious" post="orthohantavirus hantavirus. The infectious progeny virus in the cell"/>
 <result pre="and measured for the presence of infectious orthohantavirus hantavirus. The" exact="infectious" post="progeny virus in the cell supernatant was evaluated by"/>
 <result pre="j-n) or substitution with methyl groups (4f, j-n) results in" exact="total" post="loss of antiviral activity. Moreover, we can highlight that"/>
 <result pre="ethyl-group (2k) or butyl-group (2m), it turned out in a" exact="total" post="loss of antiviral activity. Derivative 2n, recently described by"/>
 <result pre="presence of the active compound during a single round of" exact="viral infection" post="was determined. Treatment with non-cytotoxic 20 µM concentration of"/>
 <result pre="of the active compound during a single round of viral" exact="infection" post="was determined. Treatment with non-cytotoxic 20 µM concentration of"/>
 <result pre="of 2j, 2l and 2n caused a significant reduction of" exact="viral" post="titer (Figure 5). A significant decline in viral titer"/>
 <result pre="reduction of viral titer (Figure 5). A significant decline in" exact="viral" post="titer of HTNV was also observed at 50 µM"/>
 <result pre="indicated doses, and RBV was used as a reference compound." exact="Viral" post="yields in the culture supernatant were determined by viral"/>
 <result pre="compound. Viral yields in the culture supernatant were determined by" exact="viral" post="titer reduction assay at day 3 post-infection. In our"/>
 <result pre="2l, 2j (20 µM) determined a very interesting reduction of" exact="viral" post="titer compared to control cells infected in the absence"/>
 <result pre="of viral titer compared to control cells infected in the" exact="absence of" post="inhibitors. The production of the virus was significantly reduced"/>
 <result pre="with 2l (3,08 log10). The same trend of reduction in" exact="viral" post="loads was detected for 2n (2,41 log10) and 2j"/>
 <result pre="µM concentration. 4. Conclusions Over the past 50 years, hantavirus" exact="infections" post="have caused severe diseases with serious clinical effects on"/>
 <result pre="Role as Emerging PathogensViruses201022559258610.3390/v212255921994631 5.GavrilovskayaI.N.BrownE.J.GinsbergM.H.MackowE.R.Cellular entry of hantaviruses which cause" exact="hemorrhagic fever with renal syndrome" post="is mediated by β3 integrinsJ. Virol.1999733951395910.1128/JVI.73.5.3951-3959.199910196290 6.JonssonC.B.SchmaljohnC.S.Replication of hantavirusesCurr."/>
 <result pre="5.GavrilovskayaI.N.BrownE.J.GinsbergM.H.MackowE.R.Cellular entry of hantaviruses which cause hemorrhagic fever with renal" exact="syndrome" post="is mediated by β3 integrinsJ. Virol.1999733951395910.1128/JVI.73.5.3951-3959.199910196290 6.JonssonC.B.SchmaljohnC.S.Replication of hantavirusesCurr."/>
 <result pre="and means of controlAntivir. Res.20035710111110.1016/S0166-3542(02)00203-612615306 8.OggM.JonssonC.B.CampJ.V.HooperJ.W.Ribavirin Protects Syrian Hamsters against" exact="Lethal" post="Hantavirus Pulmonary Syndrome—After Intranasal Exposure to Andes VirusViruses201352704272010.3390/v511270424217424 9.KrügerD.H.SchönrichG.KlempaB.Human"/>
 <result pre="of controlAntivir. Res.20035710111110.1016/S0166-3542(02)00203-612615306 8.OggM.JonssonC.B.CampJ.V.HooperJ.W.Ribavirin Protects Syrian Hamsters against Lethal Hantavirus" exact="Pulmonary" post="Syndrome—After Intranasal Exposure to Andes VirusViruses201352704272010.3390/v511270424217424 9.KrügerD.H.SchönrichG.KlempaB.Human pathogenic hantaviruses"/>
 <result pre="of intravenous ribavirin in treatment of haemorrhagic fever with renal" exact="syndrome" post="caused by puumala virusInfect. Dis.20174951452010.1080/23744235.2017.1293841 12.ChapmanL.E.MertzG.J.PetersC.J.Intravenous ribavirin for hantavirus"/>
 <result pre="syndrome caused by puumala virusInfect. Dis.20174951452010.1080/23744235.2017.1293841 12.ChapmanL.E.MertzG.J.PetersC.J.Intravenous ribavirin for hantavirus" exact="pulmonary" post="syndrome: Safety and tolerance during 1 year of open-label"/>
 <result pre="humanrespiratory syncytial virus entry inhibitorsFront. Chem.2019724710.3389/fchem.2019.0024731041309 21.PirasS.CoronaP.IbbaR.RiuF.SannaG.MadedduS.DeloguI.LoddoR.CartaA.Novel Benzotriazole Derivatives as" exact="Selective" post="Inhibitors of Coxsackies B5 virus: 1-[4-(5,6-dimethyl(H)-1H(2H)-benzotriazol-1(2)-yl)phenyl]-3-alkyl(aryl)ureaMed. Chem.202016110.2174/1573406416666191226142744 22.HeiderH.ZiajaB.PriemerC.LundkvistA.NeytsJ.KrügerD.H.UlrichR.A chemiluminescence"/>
 <result pre="reduction assay at day 7 post-infection. Figure 5 Yield of" exact="infectious" post="Hantaan (HTNV) viruses produced in infected VeroE6 cells treated"/>
</results>
